The Centre for Commercialization of Cancer Immunotherapy (C3i) is a leading brand committed to the advancement of cancer immunotherapy. At C3i, our mission is to revolutionize cancer treatment by harnessing the power of the immune system to fight against cancer cells. With a visionary board of directors and a dedicated management team, we aim to develop and deliver innovative products and services in the field of cancer immunotherapy.

Our key assets include a Biomarker and Diagnostic Unit, GMP Manufacturing Unit for Regenerative Medicine and Cancer Immunotherapy, Clinical Research Unit, Contract Research Organization, and an Innovation and Commercialization Unit. These assets enable us to conduct vital research, develop cutting-edge therapies, and bring them to market efficiently. We are constantly pushing the boundaries of cancer treatment through our commitment to innovation and collaboration.

Join us in our mission to redefine cancer care. Contact C3i today to learn more about how we are revolutionizing the fight against cancer through immunotherapy